Pembrolizumab,eftilagimod
novartis,Merck
['head and neck', 'pembro', 'eftilagimod']
from 1:15pm cdt, martin forster ( ) &amp; ' reserch is being presented on the results from a phase ii study of eftilagimod alpha + pembrolizumab in patients with metastatic head and neck squamous cell #carcinoma: #asco23
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK